How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets
The modeled fair value estimate for Castle Biosciences has been trimmed from US$47.25 to US$45.88, a reduction of about 2.9% in the price target. That shift lines up with recent Street research, where solid Q1 execution is being weighed against more cautious assumptions on what investors should pay for the stock. As you read on, you will see how these updated targets fit into the evolving analyst narrative and what that might mean for your own view on the shares. Stay updated as the Fair...